Modality
ASO
MOA
C5i
Target
EZH2
Pathway
JAK/STAT
AsthmaMM
Development Pipeline
Preclinical
~Jan 2011
→ ~Apr 2012
Phase 1
~Jul 2012
→ ~Oct 2013
Phase 2
~Jan 2014
→ ~Apr 2015
Phase 3
~Jul 2015
→ ~Oct 2016
NDA/BLA
Jan 2017
→ Jul 2031
NDA/BLACurrent
NCT07951078
1,287 pts·MM
2017-01→2031-07·Terminated
NCT03371759
1,878 pts·Asthma
2021-08→2031-06·Completed
3,165 total pts2 indications
Approved
CompletedCurrentUpcoming
Catalysts (2)
2031-06-105.2y awayPh3 Readout· Asthma
2031-07-095.3y awayPh3 Readout· MM
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
NDA/BLA
Termina…
NDA/BLA
Complet…
Catalysts
Ph3 Readout
2031-06-10 · 5.2y away
Asthma
Ph3 Readout
2031-07-09 · 5.3y away
MM
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07951078 | NDA/BLA | MM | Terminated | 1287 | Safety |
| NCT03371759 | NDA/BLA | Asthma | Completed | 1878 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| Rimabrutinib | Madrigal Pharma | Phase 1/2 | GPRC5D | |
| XEN-577 | Xenon Pharma | Phase 2/3 | C5 | |
| Voxabrutinib | Annexon | Phase 1/2 | EZH2 | |
| SLD-1824 | Solid Bio | Phase 2 | EZH2 | |
| EXA-4696 | Exscientia | Phase 2/3 | KRASG12C | |
| Gelibrutinib | Sun Pharma | NDA/BLA | EZH2 | |
| RDY-3640 | Dr Reddy's | Preclinical | EZH2 | |
| QUO-6518 | Quotient Ther | Preclinical | CD38 | |
| ONC-9948 | OncXerna | Approved | PARP |